**FDA Update on Dilated Cardiomyopathy: Fully and Partially Recovered Cases**

Center for Veterinary Medicine, U.S. Food and Drug Administration

**Abstract**

FDA has received more than 1100 reports of dilated cardiomyopathy (DCM) involving more than 1100 dogs and more than 20 cats between January 2014 and July 20, 2020. A subset of all DCM reports received were forwarded to FDA’s Veterinary Laboratory Investigation and Response Network (Vet-LIRN) for medical record review and owner dietary and environmental exposure interviews. Vet-LIRN collected clinical information for more than 150 dogs with DCM and divided them into two groups. Group One consists of DCM reports received between January 2018 and April 2019 and includes 121 dogs. Group Two consists of DCM reports received between November 2019 and July 2020 and includes approximately 40 dogs. Both groups were evaluated for factors that might affect diagnosis and recovery from DCM, such as comorbidities and historical illnesses. Additionally, FDA reviewed medical treatment and echocardiographic changes over time to monitor for signs of recovery or disease progression. Ingredient evaluations were performed on diets reported to have been fed prior to diagnosis. Most dogs with full or partial recovery of DCM had a diet change after diagnosis, and ingredient evaluations were performed on the recovery diets fed to full recovery cases. Vet-LIRN continues to follow both groups of dogs over time, and the data furthers the collective understanding of DCM in dogs with varying degrees of recovery.